Using a recently established porcine model, it was clearly shown that oral histamine administration is extremely dangerous in the presence of diamine oxidase (DAO) blockade. Due to the severity of the symptoms (20% death) and the clinical relevance, further interest has been focussed on strategies to prevent or alleviate food induced histaminosis. In a randomized controlled trial, 10 pigs under DAO blockade were challenged with oral histamine (60 mg). Half of these animals received a prophylactic premedication with a combination of H1- and H2-receptor antagonists. As expected, all animals developed a massive increase in plasma histamine levels, with significantly higher values in the control group (median: 123 ng/ml) compared to the antihistamine group (median: 32 ng/ml). In contrast, clinical symptoms were only observed in the control group. The maximum fall in mean arterial pressure (hypotension) was 60 mmHg (median for control group) but only 15 mmHg (median) under antihistamine pretreatment. These results firstly provide further evidence for the causal role of histamine in the new disease concept and secondly enable us to investigate appropriate therapeutic measures for patients at risk.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF02222242 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Malian field isolates provide insight into Plasmodium malariae intra-erythrocytic development and invasion.
PLoS Negl Trop Dis
January 2025
Malaria Research and Training Center (MRTC), Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Bamako, Mali.
Plasmodium malariae is the third most prevalent human malaria parasite species and contributes significantly to morbidity. Nevertheless, our comprehension of this parasite's biology remains limited, primarily due to its frequent co-infections with other species and the lack of a continuous in vitro culture system. To effectively combat and eliminate this overlooked parasite, it is imperative to acquire a better understanding of this species.
View Article and Find Full Text PDFEngineering Semiconducting Polymeric Nanoagonists Potentiate cGAS-STING Pathway Activation and Elicit Long Term Memory Against Recurrence in Breast Cancer.
Adv Mater
December 2024
Department of Hyperbaric Oxygen Medicine, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Center for Geriatric, Shenzhen People's Hospital, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, 518020, P. R. China.
Article Synopsis
- - Triple-negative breast cancer has a "cold" microenvironment that resists current immunotherapy, but activating the STING pathway shows potential for improving treatment effectiveness.
- - The study combines photothermal therapy (PTT) using a semiconductor nano-agent (DPTT-Mn Lipo NPs) with innate immune responses to reprogram the immune-suppressive environment and enhance anti-tumor immunity.
- - This approach not only triggers cell death and activates immune cells but also works well with anti-PD-1 therapy to create lasting immune memory, helping to prevent tumor recurrence.
Article Synopsis
- Immune-related adverse events (irAEs) from immune checkpoint blockade (ICB) therapy affect many cancer patients, with their underlying causes not fully understood.
- Research identified a bio-active lipid called linoleoyl-lysophosphatidylcholine (LPC 18:2) that may play a key role in modulating these adverse events, with low levels of LPC 18:2 linked to the onset of severe irAEs.
- Supplementing LPC 18:2 in preclinical and human studies showed a reduction in harmful inflammation and neutrophil levels without detracting from the anti-tumor effectiveness of ICB therapy, suggesting it could enhance patient outcomes.
An ultrasound-activated nanoplatform remodels tumor microenvironment through diverse cell death induction for improved immunotherapy.
J Control Release
June 2024
Department of Cardiology, Shenzhen Cardiovascular Minimally Invasive Medical Engineering Technology Research and Development Center, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen 518020, Guangdong, PR China; Department of Traditional Chinese Medicine, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong 510515, PR China; State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China; State Key Laboratory of Antiviral Drugs, School of Pharmacy, Henan University, Kaifeng 475004, China; Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. Electronic address:
Article Synopsis
- Nanomaterial-based nanomedicine is primarily focused on traditional apoptosis for cancer treatment, but there is a growing need to incorporate alternative cell death methods like ferroptosis and immunogenic cell death to boost the immune response against tumors.
- A new multifunctional nanocomposite called HFT NPs was developed, combining HMME, Fe, and Tannic acid to induce various cell death pathways and improve the tumor microenvironment, using ultrasound for enhanced efficacy.
- The study found that HFT NPs, when paired with ultrasound, can produce reactive oxygen species and reshape the tumor microenvironment to increase T cell infiltration, showing promise for more effective cancer treatments, especially in tumors with low immunogenicity.
ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype.
J Exp Med
April 2024
Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
We have previously demonstrated synergy between ICOS costimulation (IVAX; ICOSL-transduced B16-F10 cellular vaccine) and CTLA-4 blockade in antitumor therapy. In this study, we employed CyTOF and single-cell RNA sequencing and observed significant remodeling of the lymphoid and myeloid compartments in combination therapy. Compared with anti-CTLA-4 monotherapy, the combination therapy enriched Th1 CD4 T cells, effector CD8 T cells, and M1-like antitumor proinflammatory macrophages.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!